Acute myocardial infarction (AMI) is a non-transmissible condition with high prevalence, morbidity,
and mortality. Different strategies for the management of AMI are employed worldwide, but its early diagnosis
remains a major challenge. Many molecules have been proposed in recent years as predictive agents in the early
detection of AMI, including troponin (C, T, and I), creatine kinase MB isoenzyme, myoglobin, heart-type fatty
acid-binding protein, and a family of histone deacetylases with enzymatic activities named sirtuins. Sirtuins may
be used as predictive or complementary treatment strategies and the results of recent preclinical studies are promising.
However, human clinical trials and data are scarce, and many issues have been raised regarding the predictive
values of sirtuins. The present review summarizes research on the predictive value of sirtuins in AMI. We
also briefly summarize relevant clinical trials and discuss future perspectives and possible clinical applications.